Atossa Therapeutics, Inc. (NASDAQ:ATOS - Get Free Report) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.39 and traded as high as $1.50. Atossa Therapeutics shares last traded at $1.50, with a volume of 362,114 shares traded.
Analysts Set New Price Targets
Several analysts recently issued reports on the stock. Ascendiant Capital Markets increased their price target on shares of Atossa Therapeutics from $6.25 to $6.50 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. StockNews.com downgraded shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, August 12th. Finally, HC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of Atossa Therapeutics in a research note on Monday, August 12th.
Get Our Latest Research Report on Atossa Therapeutics
Atossa Therapeutics Price Performance
The firm has a market capitalization of $183.61 million, a PE ratio of -6.08 and a beta of 1.20. The firm's fifty day moving average is $1.42 and its two-hundred day moving average is $1.39.
Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. As a group, equities research analysts predict that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.
Hedge Funds Weigh In On Atossa Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of ATOS. XTX Topco Ltd purchased a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at $29,000. Cetera Advisors LLC purchased a new stake in shares of Atossa Therapeutics in the 1st quarter valued at $72,000. SG Americas Securities LLC boosted its stake in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company's stock valued at $64,000 after purchasing an additional 30,037 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of Atossa Therapeutics in the 1st quarter valued at $151,000. Finally, Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics in the 2nd quarter valued at $161,000. Hedge funds and other institutional investors own 12.74% of the company's stock.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
See Also
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
